OakChart

Pliant Therapeutics Inc

PLRXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 10:33 AM ET

0.7600-0.0257 (-3.27%)
2026-11-11 16:35 CET
Market cap
48.65 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-92.29 USD m
Free cash flow, TTM
-70.89 USD m
EPS diluted, TTM
-1.50
P/E
-
Compare

Price

PLRX against its 20, 50 and 200-day averages
2050200beatmiss
0.801.001.201.401.3M2.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PLRXclose 0.7620-day 0.8650-day 0.99200-day 1.140.76

58.1% under the 52-week high of 1.82 on 12 Nov 2025. 52-week low 0.76 on 11 Nov 2026. Last 15 sessions, 18.8% high to low

Profile

PLRX
52-week range, 0% of the way up
0.771.82

Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. It offers a product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Employees49
IPOJun 03, 2020
Beta1.36
ATR, 14d0.04
Rel volume0.44
Short float8.10%
Insider own2.64%
Inst own77.70%

Snapshot

6 groups

Valuation

Index-
Market Cap47.06M
Enterprise Value-82.30M
Income-92.29M
Sales0.00M
Book/sh2.37
Cash/sh2.55
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees49
IPOJun 03, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.32
P/C0.30
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.90
Current Ratio9.90
Debt/Eq0.20
LT Debt/Eq0.18
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.50
EPS next Y-1.36
EPS next Q-0.37
EPS this Y41.07%
EPS next Y5.16%
EPS next 5Y23.86%
EPS past 3/5Y6.05% -15.81%
Sales past 3/5Y- -
EPS Y/Y TTM55.84%
Sales Y/Y TTM-
EPS Q/Q48.78%
Sales Q/Q-
EarningsAug 11 AMC
EPS/Sales Surpr.-5.32% -

Ownership

Insider Own2.64%
Insider Trans0.00%
Inst Own77.70%
Inst Trans-7.11%
ROA-37.69%
ROE-50.29%
ROIC-53.22%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-11.30%
SMA50-23.35%
SMA200-33.50%
Trades-

Technical

Shs Outstand61.92M
Shs Float60.29M
Short Float8.10%
Short Ratio12.41
Short Interest4.88M
52W High1.82 -58.13%
52W Low0.77 -1.30%
Volatility5.39% 5.88%
ATR (14)0.04
RSI (14)26.76
Beta1.36
Rel Volume0.44
Avg Volume393.46K
Volume35,801

Performance

Perf Week-10.78%
Perf Month-21.49%
Perf Quarter-29.63%
Perf Half Y-35.04%
Perf YTD-37.70%
Perf Year-54.49%
Perf 3Y-94.50%
Perf 5Y-95.45%
Perf 10Y-
Recom3.50
Target Price1.51
Prev Close0.79
Price0.76
Change %-3.27%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 10, 2025DowngradeJJP MorganNeutral → Underweight
Mar 04, 2025ResumedCCantor FitzgeraldNeutral
Mar 04, 2025DowngradeNNeedhamBuy → Hold
Mar 03, 2025DowngradeSStifelBuy → Hold
Mar 03, 2025DowngradeLLeerink PartnersOutperform → Market Perform
Feb 10, 2025DowngradeWWells FargoOverweight → Equal Weight$41 → $4+426.3%
Feb 10, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$45 → $4+426.3%
Feb 10, 2025DowngradeOOppenheimerOutperform → Perform
Feb 10, 2025DowngradeJJP MorganOverweight → Neutral
Feb 10, 2025DowngradeHH.C. WainwrightBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
XLOXilio Therapeutics Inc57.91M
HOWLWerewolf Therapeutics Inc47.63M
AGENAgenus Inc322.61M
BCAXBicara Therapeutics Inc726.94M
CMPXCompass Therapeutics Inc147.52M
RCUSArcus Biosciences Inc2.68B
SRRKScholar Rock Holding Corp5.76B
IOVAIovance Biotherapeutics Inc3.72B
CADLCandel Therapeutics Inc713.92M
DYNDyne Therapeutics Inc3.37B

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Cummings Keith LamontChief Financial OfficerJan 20 '26Sale1.2824,00230,723297,214Jan 22 09:46 PM
Cheung LilyChief Human Resource OfficerJan 20 '26Sale1.287,5349,64444,847Jan 22 09:38 PM
Coulie BernardPresident and CEOJan 20 '26Sale1.2889,375114,400505,601Jan 22 09:38 PM
Kuo MinnieChief Operating OfficerJan 20 '26Sale1.286,9178,85437,806Jan 22 09:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B

News

latest 14 of 206
  • Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference (MarketBeat)
  • Align downgraded, NetEase upgraded: Wall Street's top analyst calls (The Fly)
  • Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
  • Pliant halts bexotegrast development for IPF after trial results (Clinical Trials Arena) -7.20%
  • Pliant Therapeutics Provides Update on BEACON-IPF (GlobeNewswire)
  • Loading…
  • Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference (GlobeNewswire)
  • Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
  • Pliant cuts workforce by 45% following lung trial termination (Clinical Trials Arena)
  • Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma (BioPharma Dive)
  • Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations (GlobeNewswire)
  • PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know (Zacks)
  • Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference (GlobeNewswire) -6.72%
  • Pliant Therapeutics: An Activist On Deck (Seeking Alpha) -7.09%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.360-0.342-0.3610.000.005
2026Q12026-05-11-0.320-0.357-0.3240.000.006
2025Q42026-03-11-0.380-0.379-0.3840.000.005
2025Q32025-11-06-0.430-0.524-0.4280.000.008
2025Q22025-08-07-0.710-0.677-0.7050.000.009
2025Q12025-05-08-0.920-0.767-0.9170.000.0012
2024Q42025-03-03-0.820-0.956-0.8170.000.0011
2024Q32024-11-07-0.950-0.969-0.9510.000.4712
2024Q22024-08-07-0.920-0.849-0.9250.000.7312
2024Q12024-05-06-0.780-0.772-0.7800.000.5813
2023Q42024-02-27-0.690-0.814-0.6860.000.8113
2023Q32023-11-09-0.700-0.775-0.6950.001.0212
2023Q22023-08-09-0.700-0.713-0.6960.251.2112
2023Q12023-05-09-0.670-0.668-0.6701.331.3912
2022Q42023-03-09-0.720-0.700-0.7191.971.4512
2022Q32022-11-08-0.650-0.741-0.6541.481.7910

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-1.950-2.166-1.16841.8239.43
2021FY-2.710-2.793-2.7137.577.72
2022FY-2.940-2.895-2.9359.698.99
2023FY-2.750-2.889-2.7481.582.29
2024FY-3.470-3.564-3.4740.000.00
2025FY-2.430-2.426-2.4310.000.00
2026FY--1.432--0.00
2027FY--1.358--0.00
2028FY--1.073---
2029FY--0.860---
2030FY--0.180--200

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-121000.000.000.00
2026Q3S2026-06-261000.000.000.00
2026Q3S2026-05-122000.000.000.00
2026Q3S2026-03-122000.000.000.00
2026Q3S2025-11-161000.000.000.00
2026Q3S2025-11-122000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00
2026Q3S2025-11-073000.000.000.00
2026Q3S2025-11-063000.000.000.00
2026Q3S2025-11-053000.000.000.00
2026Q3S2025-11-043000.000.000.00

Estimate history

EPS, annual-0.989-0.193-1.168-2.713-2.935-2.748-3.474-2.434-1.4975
Period20182019202020212022202320242025TTM
EPS, quarterly-0.925-0.951-0.817-0.917-0.705-0.428-0.384-0.324-0.361
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual057.05241.8177.5729.6851.58000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual35.55135.55135.55336.08348.94159.92160.86161.44961.92
Period20182019202020212022202320242025MRQ
Shares, quarterly60.42560.8560.86161.38661.38661.44961.44961.91561.92
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.001.589.697.5741.8257.050.00
Cost of Goods Sold Incl. D&A1.311.702.121.843.683.20--0.67
Gross Profit-1.31-1.70-2.12-0.266.004.37---0.67
Selling, General and Administrative Excl. Other93.57148.38226.24183.88133.20101.9082.1557.1730.25
Research and Development60.22102.46167.19125.9693.2574.3464.8847.3524.41
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-94.88-150.07-228.37-184.15-127.20-97.53-41.65-1.23-30.91
Interest Expense-2.563.021.270.790.000.000.000.00
Unusual Expense4.438.130.000.00-0.000.000.00-
Net Income Before Taxes-92.29-149.34-210.30-161.34-123.32-97.26-41.53-0.63-30.28
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-92.29-149.34-210.30-161.34-123.32-97.26-41.53-0.63-30.28
Net Income From Continuing Operations-92.29-149.34-210.30-161.34-123.32-97.26-41.53-0.63-30.28
Net Income-92.29-149.34-210.30-161.34-123.32-97.26-41.53-6.86-35.15
EPS (Recurring)-1.44-2.34-3.47-2.75-2.94-2.71-1.17-0.19-0.99
EPS (Basic, Before Extraordinaries)-1.50-2.43-3.47-2.75-2.94-2.71-1.17-0.19-0.99
EPS (Diluted)-1.50-2.43-3.47-2.75-2.94-2.71-1.17-0.19-0.99
EBITDA-93.57-148.38-226.24-182.30-123.52-94.33-40.34-0.12-30.25
Non-Operating Income (Expense)7.9711.4221.0924.084.670.270.110.600.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense19.3926.2437.6344.4822.6010.443.901.830.23
Price To Sales Ratio---673.0483.8663.9119.32--
Gross Margin----16.5261.9957.69---
Operating Margin----11,654.75-1,313.37-1,288.10-99.59-2.16-
Net Margin----10,211.14-1,273.32-1,284.51-99.32-12.02-
Shares Outstanding61.9261.4560.8659.9248.9436.0835.5535.5535.55
Market Capitalization48.6548.65801.441,084.72942.52486.53806.10827.75-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.250.260.360.440.450.450.460.53
Gross Profit-0.25-0.26-0.36-0.44-0.45-0.45-0.46-0.53
Selling, General and Administrative Excl. Other23.6121.5120.7127.7345.1558.4952.8661.48
Research and Development16.4813.3213.0217.4031.7542.9938.3447.22
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.86-21.77-21.08-28.17-45.59-58.94-53.32-62.01
Interest Expense0.00-0.140.810.810.800.830.88
Unusual Expense0.000.004.330.100.000.000.000.00
Net Income Before Taxes-22.37-20.04-23.58-26.30-43.30-56.17-49.73-57.76
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-22.37-20.04-23.58-26.30-43.30-56.17-49.73-57.76
Net Income From Continuing Operations-22.37-20.04-23.58-26.30-43.30-56.17-49.73-57.76
Net Income-22.37-20.04-23.58-26.30-43.30-56.17-49.73-57.76
EPS (Recurring)-0.36-0.32-0.33-0.43-0.71-0.92-0.82-0.95
EPS (Basic, Before Extraordinaries)-0.36-0.32-0.38-0.43-0.71-0.92-0.82-0.95
EPS (Diluted)-0.36-0.32-0.38-0.43-0.71-0.92-0.82-0.95
EBITDA-23.61-21.51-20.71-27.73-45.15-58.49-52.86-61.48
Non-Operating Income (Expense)1.491.731.962.783.103.574.425.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.194.254.536.426.388.918.428.90
Shares Outstanding61.9261.9161.4561.4561.3961.3960.8660.85
Market Capitalization48.6578.0174.9790.8571.2182.67801.44681.58

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments190.94355.72494.25331.19200.60276.89102.7760.95
Short Term Receivables0.822.303.003.142.479.367.380.50
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets4.684.248.265.986.384.501.740.28
Total Current Assets196.45362.26505.50340.31209.44290.75111.9061.73
Net Property, Plant & Equipment26.9132.774.789.9110.944.324.084.26
Total Investments and Advances1.481.481.480.000.000.000.000.00
Deferred Tax Assets5.34-------
Other Assets0.390.430.390.390.840.453.080.54
Total Assets230.57396.95512.15350.61221.22295.53119.0666.53
Short Term Debt Incl. Current Port. of LT Debt1.450.541.322.461.870.000.000.00
Accounts Payable0.485.964.531.582.972.021.252.58
Other Current Liabilities14.4426.7222.6819.8811.999.586.922.51
Total Current Liabilities16.3633.2228.5223.9116.8311.608.175.08
Long Term Debt27.6659.6510.0513.365.330.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities5.34-------
Other Liabilities0.000.000.000.000.000.870.910.81
Total Liabilities49.3692.8738.5837.2722.1612.469.085.89
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00186.28132.10
Common Equity181.21304.08473.58313.34199.06283.06-76.30-71.47
Total Shareholders Equity181.21304.08473.58313.34199.06283.06109.9860.63
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity181.21304.08473.58313.34199.06283.06109.9860.63
Total Liabilities & Stockholders Equity230.57396.95512.15350.61221.22295.53119.0666.53
Book Value Per Share2.955.007.906.405.527.96-2.15-2.01
Tangible Book Value Per Share2.955.007.906.405.527.96-2.15-2.01
Full-Time Employees49171158124917862-
Price to Book Ratio0.332.322.162.802.452.852.75-
Return on Assets-47.60-46.27-37.40-43.13-37.64-20.04-0.68-
Return on Equity-61.55-54.09-41.00-48.13-40.35-21.13-0.74-
Return on Invested Capital-71.50-57.82-33.36-37.75-47.59-14.67-0.57-49.93
Quick Ratio12.0010.9117.7214.2312.4425.0713.6912.14
Current Ratio12.0010.9117.7214.2312.4425.0713.6912.14

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-92.29-149.34-210.30-161.34-123.32-97.26-41.53-0.63-30.28
Depreciation1.311.702.121.843.683.201.311.110.67
Other Funds (Non Cash)25.3235.2543.5941.8820.7911.704.161.830.23
Funds from Operations-65.66-112.40-164.59-117.61-98.85-82.36-36.062.31-29.38
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.24-15.949.091.254.226.92-1.21-5.061.05
Cash from Operating Activities-70.89-128.34-155.50-116.36-94.63-75.44-37.27-2.75-28.33
Capital Expenditures0.00-0.37-3.85-0.92-1.76-1.95-1.53-0.96-2.32
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.270.150.000.000.000.000.000.000.00
Purchase or Sale of Investments40.80134.51144.19-126.09-148.4475.65-209.33-16.970.00
Purchase of Investments-219.86-203.40-211.28-583.07-325.72-219.89-322.61-16.970.00
Sale Or Maturity of Investments260.67337.91355.47456.98177.27295.54113.270.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities41.08134.29140.34-127.01-150.2073.70-210.87-17.93-2.32
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.150.570.00269.40215.642.53213.2148.1287.35
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.150.570.00269.40215.642.53213.2148.1287.35
Proceedsfrom Stock Options0.150.570.00269.40215.642.53212.7747.9587.35
Issuance or Reduction of Debt, Net-32.27-32.270.000.000.000.000.000.000.00
Change in Long Term Debt-32.27-32.270.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-32.27-32.270.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.0023.125.0011.210.000.00-2.580.00
Other Financing Activities Uses0.000.000.000.000.000.000.00-2.580.00
Cash from Financing Activities-32.12-31.7023.12274.40226.852.53213.2145.5487.35
Net Change in Cash-61.94-25.747.9531.03-17.980.78-34.9224.8656.70
Free Cash Flow-70.89-128.71-159.35-117.28-96.39-77.40-38.80-3.71-30.65
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments158.10170.89190.94241.80262.87305.64
Short Term Receivables0.870.910.820.911.531.68
Inventories0.000.000.000.000.000.00
Other Current Assets4.173.124.682.883.043.86
Total Current Assets163.14174.93196.45245.59267.44311.19
Net Property, Plant & Equipment24.7025.8026.9129.1430.5131.67
Total Investments and Advances1.481.481.481.481.481.48
Deferred Tax Assets--5.34---
Other Assets0.550.390.390.390.390.43
Total Assets189.88202.60230.57276.60299.82344.77
Short Term Debt Incl. Current Port. of LT Debt2.271.711.451.191.230.77
Accounts Payable1.530.360.480.481.385.62
Other Current Liabilities12.688.2814.4415.9517.9821.81
Total Current Liabilities16.4810.3616.3617.6220.5928.20
Long Term Debt26.4727.0727.6658.6759.1559.40
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--5.34---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities42.9537.4349.3676.2979.7487.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity146.93165.17181.21200.31220.08257.16
Total Shareholders Equity146.93165.17181.21200.31220.08257.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity146.93165.17181.21200.31220.08257.16
Total Liabilities & Stockholders Equity189.88202.60230.57276.60299.82344.77
Book Value Per Share2.372.672.953.263.594.19
Tangible Book Value Per Share2.372.672.953.263.594.19
Full-Time Employees--49---
Price to Book Ratio0.330.430.370.410.280.27
Return on Assets-37.69-41.37-47.60-48.60-52.83-50.67
Return on Equity-50.29-53.62-61.55-64.27-67.55-63.22
Return on Invested Capital-12.90-10.42-11.29-10.16-15.51-17.74
Quick Ratio9.9016.8912.0013.9312.9911.03
Current Ratio9.9016.8912.0013.9312.9911.03

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-22.37-20.04-23.58-26.30-43.30-56.17
Depreciation0.250.260.360.440.450.45
Other Funds (Non Cash)4.915.417.467.539.1711.09
Funds from Operations-17.21-14.36-15.75-18.34-33.68-44.63
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.41-4.87-2.04-2.75-6.92-4.23
Cash from Operating Activities-12.80-19.23-17.79-21.08-40.60-48.86
Capital Expenditures0.000.000.000.00-0.11-0.26
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.10-0.000.160.000.00
Purchase or Sale of Investments15.47-4.201.7727.7735.6069.38
Purchase of Investments-17.32-64.90-85.08-52.56-51.61-14.15
Sale Or Maturity of Investments32.7960.7086.8580.3387.2183.53
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities15.49-4.101.7727.9235.4969.11
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.070.000.070.000.50
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.070.000.070.000.50
Proceedsfrom Stock Options0.000.070.000.070.000.50
Issuance or Reduction of Debt, Net0.000.00-32.270.000.000.00
Change in Long Term Debt0.000.00-32.270.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-32.270.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.07-32.270.070.000.50
Net Change in Cash2.69-23.25-48.296.91-5.1220.75
Free Cash Flow-12.80-19.23-17.79-21.08-40.72-49.13

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.10%4.9M60.3M395.96K
2026-10-157.69%4.6M60.3M429.93K
2026-09-307.04%4.2M60.3M494.44K
2026-09-156.12%3.7M60.3M495.49K
2026-08-315.44%3.3M60.3M515.04K
2026-08-144.59%2.8M60.3M531.29K
2026-07-314.90%2.8M57.3M524.36K
2026-07-154.92%2.8M57.3M552.13K
2026-06-304.51%2.6M57.3M479.56K
2026-06-154.91%2.8M57.3M502.94K
2026-05-295.99%3.4M57.3M494.92K
2026-05-156.01%3.4M57.3M529.72K
2026-04-305.99%3.4M57.3M608.78K
2026-04-156.38%3.6M57.1M662.46K
2026-03-317.06%4.0M57.1M782.18K
2026-03-136.66%3.8M57.1M835.09K
2026-02-276.68%3.8M56.6M1.23M
2026-02-137.34%4.2M56.6M1.23M
2026-01-307.38%4.2M56.6M1.22M
2026-01-156.62%3.8M56.6M1.24M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.005.3200.000.000.188-0.0090.000
call5.000.001.000.007.1270.000.000.160-0.0110.000
call7.500.001.000.008.0750.000.000.150-0.0120.000
put2.501.252.251.7014.7720.000.00-0.812-0.0090.000
put5.003.704.700.0016.7150.000.00-0.840-0.0110.000
put7.506.207.200.0017.7730.000.00-0.850-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-023Initial statement of beneficial ownership of securities2026-09-30SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-133Initial statement of beneficial ownership of securities2026-07-09SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-138-KCurrent report2026-07-09SEC
2026-07-133Initial statement of beneficial ownership of securities2026-07-09SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-22ARSAnnual report to security holders. 2025-12-31SEC
2026-04-22DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-22DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-174Statement of changes in beneficial ownership of securities2026-04-17SEC
2026-04-174Statement of changes in beneficial ownership of securities2026-04-17SEC
2026-04-174Statement of changes in beneficial ownership of securities2026-04-17SEC
2026-04-174Statement of changes in beneficial ownership of securities2026-04-17SEC
2026-04-178-KCurrent report2026-04-14SEC
2026-04-06EFFECTEffectiveness filing by commission orderSEC
2026-04-02CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-0100163.62K4
2025-120000
2025-110000

Institutional holders

Manager% owned
TANG CAPITAL MANAGEMENT LLC9.92%
ADAR1 Capital Management, LLC8.90%
VANGUARD CAPITAL MANAGEMENT LLC3.94%
ACADIAN ASSET MANAGEMENT LLC3.90%
TWO SIGMA INVESTMENTS, LP3.65%
CITADEL ADVISORS LLC3.46%
RENAISSANCE TECHNOLOGIES LLC3.31%
Monaco Asset Management SAM3.24%
Lynx1 Capital Management LP2.90%
BML Capital Management, LLC2.50%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.82%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Ultra-Small Company Fund0.76%
Fidelity Extended Market Index Fund0.57%
iShares Micro-Cap ETF0.33%
Goldman Sachs Absolute Return Tracker Fund0.26%
VANGUARD HEALTH CARE INDEX FUND0.25%
Invesco RAFI US 1500 Small-Mid ETF0.17%
Fidelity Total Market Index Fund0.15%
Ultra-Small Company Market Fund0.13%

OakChart. PLRX. Cached 15 minutes.